Respiratory syncytial virus vaccines
RESPIRATORY SYNCYTIAL VIRUS VACCINES. Respiratory syncytial virus (RSV) is responsible for lower respiratory infections, particularly in children under five years of age (acute infant bronchiolitis) and the elderly over 60. Monoclonal antibodies (palivizumab and nirsevimab) are used to prevent bronchiolitis. Four types of vaccine are currently under development: subunit vaccines composed of recombinant proteins or viral pseudoparticles, messenger RNA vaccines, recombinant vector vaccines and live attenuated vaccines. They are indicated for pregnant women to protect infants against bronchiolitis in the first months of life, and for people over 60 or with comorbidities.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
La Revue du praticien - 73(2023), 8 vom: 05. Okt., Seite 895-898 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Vaccins contre le virus respiratoire syncytial |
|---|
| Beteiligte Personen: |
Le Hingrat, Quentin [VerfasserIn] |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 15.02.2024 Date Revised 15.02.2024 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM368441237 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368441237 | ||
| 003 | DE-627 | ||
| 005 | 20240215232134.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240214s2023 xx |||||o 00| ||fre c | ||
| 028 | 5 | 2 | |a pubmed24n1294.xml |
| 035 | |a (DE-627)NLM368441237 | ||
| 035 | |a (NLM)38354016 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Le Hingrat, Quentin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Respiratory syncytial virus vaccines |
| 246 | 3 | 3 | |a Vaccins contre le virus respiratoire syncytial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.02.2024 | ||
| 500 | |a Date Revised 15.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a RESPIRATORY SYNCYTIAL VIRUS VACCINES. Respiratory syncytial virus (RSV) is responsible for lower respiratory infections, particularly in children under five years of age (acute infant bronchiolitis) and the elderly over 60. Monoclonal antibodies (palivizumab and nirsevimab) are used to prevent bronchiolitis. Four types of vaccine are currently under development: subunit vaccines composed of recombinant proteins or viral pseudoparticles, messenger RNA vaccines, recombinant vector vaccines and live attenuated vaccines. They are indicated for pregnant women to protect infants against bronchiolitis in the first months of life, and for people over 60 or with comorbidities | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bronchiolitis Obliterans | |
| 650 | 7 | |a Respiratory Syncytial Virus Vaccines |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 700 | 1 | |a Bouzid, Donia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t La Revue du praticien |d 1951 |g 73(2023), 8 vom: 05. Okt., Seite 895-898 |w (DE-627)NLM000023248 |x 2101-017X |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2023 |g number:8 |g day:05 |g month:10 |g pages:895-898 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2023 |e 8 |b 05 |c 10 |h 895-898 | ||